Apnimed Posts $29.5M Q3 Loss as Launch Costs Surge Ahead of Feb 2027 PDUFA
APMD sits 22% above its 52-week low of $13.88.
Summary
Apnimed burned $29.5 million in Q3 2026 versus a $10.9 million loss a year earlier, driven by G&A jumping to $22.6 million from $6.0 million as it staffs up for a potential Oxnimbi launch. R&D rose 20% to $11.8 million, with the increase concentrated in medical affairs and headcount rather than new trials. The balance sheet is the story: $351.8 million in cash after the August IPO's roughly $198.9 million in net proceeds, enough to fund commercial readiness through the FDA decision. The AD109 NDA remains under review with a PDUFA goal date of February 28, 2027, and the company presented five CHEST abstracts including two late-breakers on Phase 3 data. This follows the November 13th 8-K and 10-Q/A restating the $85.4 million SASS gain into discontinued operations — no change to net income, cash or equity, but a governance overhang worth noting. The February 28, 2027 PDUFA date is the binary event that matters.
At the time of this announcement, APMD was trading at $16.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $704.4M. The 52-week trading range was $13.88 to $35.29. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.